Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Obinutuzumab (GA101) is a novel glycoengineered type II CD20 antibody in development for non-Hodgkin lymphoma. We compared the anti-tumor activity of obinutuzumab and rituximab in preclinical studies using subcutaneous Z138 and WSU-DLCL2 xenograft mouse models. Obinutuzumab and rituximab were assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Herting, Frank, Friess, Thomas, Bader, Sabine, Muth, Gunter, Hölzlwimmer, Gabriele, Rieder, Natascha, Umana, Pablo, Klein, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2014
Materias:
Original Article: Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196549/
https://www.ncbi.nlm.nih.gov/pubmed/24304419
http://dx.doi.org/10.3109/10428194.2013.856008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196549/
https://www.ncbi.nlm.nih.gov/pubmed/24304419
http://dx.doi.org/10.3109/10428194.2013.856008

Ejemplares similares